| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| ILA-H5252 | Human | Human IL-3 R alpha / CD123 Protein, Fc Tag (MALS & SPR verified) |  |
|
|
| ILA-C52H3 | Canine | Canine IL-3 R alpha / CD123 Protein, His Tag |  |
|
|
| ILA-H82H5 | Human | Biotinylated Human IL-3 R alpha / CD123 Protein, His,Avitag™ (MALS verified) |  |
|
|
| ILA-HF2H9 | Human | FITC-Labeled Human IL-3 R alpha / CD123 Protein, His Tag |  |
|
|
| ILA-M52H4 | Mouse | Mouse IL-3 R alpha / CD123 Protein, His Tag (SPR verified) |  |
|
|
| ILA-C52H6 | Cynomolgus | Cynomolgus IL-3 R alpha / CD123 Protein, His Tag (SPR verified) |  |
|
|
| ILA-H5255 | Human | Human IL-3 R alpha / CD123 Protein, Llama IgG2b Fc Tag, low endotoxin |  |
|
|
| ILA-H52H6 | Human | Human IL-3 R alpha / CD123 Protein, His Tag (MALS & SPR verified) |  |
|
|
Anti-IL-3 R alpha Antibody, Human IgG1 immobilized on CM5 Chip can bind Human IL-3 R alpha, Fc Tag (Cat. No. ILA-H5252) with an affinity constant of 50.3 nM as determined in a SPR assay (Biacore T200) (QC tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Tagraxofusp-erzs | SL-401; DTIL-3; DT388 IL3 | Approved | Texas A&M University Development Foundation | Elzonris | EU | Blastic Plasmacytoid Dendritic Cell Neoplasm; Lymphoma | s:25:"Stemline Therapeutics Inc"; | 2018-12-21 | Blastic Plasmacytoid Dendritic Cell Neoplasm; Lymphoma | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| KHK-2823 | KHK-2823 | Phase 1 Clinical | Kyowa Hakko Kirin | Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
| CD123/CLL1 CAR-T Cell Therapy (Fujian Medical University) | Phase 3 Clinical | Fujian Medical University | Leukemia, Myeloid, Acute | Details | |
| Anti-CD123 CAR-T cell therapy (Wuhan Union Hospital) | Phase 1 Clinical | Wuhan Union Hospital | Leukemia, Myeloid, Acute | Details | |
| Anti-CD123 CAR T cell therapy (Shanghai GeneChem) | Phase 1 Clinical | Shanghai Genechem Co Ltd | Leukemia, Myeloid, Acute | Details | |
| Anti-CD123 CAR T-cell therapy (Southwest Hospital) | Phase 2 Clinical | Southwest Hospital Chongqing | Leukemia, Myeloid | Details | |
| CD123 CAR-T cells (Hebei Senlang Biotechnology) | Phase 1 Clinical | Hebei Senlang Biological Technology Co Ltd | Leukemia, Myeloid, Acute | Details | |
| UniCAR-T-CD-123 | UniCAR-T-CD123 | Phase 1 Clinical | Gemoab Monoclonals Gmbh | Blastic Plasmacytoid Dendritic Cell Neoplasm; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute | Details |
| APVO436 | APVO-436 | Phase 1 Clinical | Aptevo | Myelodysplastic Syndromes; Myeloproliferative Disorders; Leukemia, Myeloid, Acute | Details |
| CD123 CAR-T cell therapy | Phase 2 Clinical | Chongqing Precision Biotechnology Co Ltd | Leukemia, Myeloid; Leukemia; Leukemia, Myeloid, Acute | Details | |
| Flotetuzumab | MGD-006; S-80880 | Phase 2 Clinical | Macrogenics | Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
| Anti-CD123 CAR T-cell therapy (University of Pennsylvania/Novartis) | Phase 1 Clinical | Novartis Pharma Ag, University Of Pennsylvania | Leukemia, Myeloid, Acute | Details | |
| Anti-CD123 chimeric antigen receptor T cell therapy (Chongqing Precision Biotech) | Phase 2 Clinical | Chongqing Precision Biotechnology Co Ltd | Leukemia, Myeloid, Acute | Details | |
| JNJ-63709178 | JNJ-9178; CNTO-9958; JNJ-63709178 | Phase 1 Clinical | Janssen Global Services Llc, Genmab | Leukemia, Myeloid, Acute | Details |
| Anti-CD123 CAR T-cell therapy (Nanjing Legend Biotech) | Phase 1 Clinical | Nanjing Legend Biotechnology Co Ltd | Leukemia, Myeloid, Acute | Details | |
| CSL-360 | IL-3Rα; CSL-360 | Phase 1 Clinical | Csl Ltd | Leukemia, Myeloid, Acute | Details |
| Talacotuzumab | CSL-362; JNJ-473; CSL-362-AML; JNJ-56022473; IL-13 MAb-CSL | Phase 3 Clinical | Csl Ltd | Myelodysplastic Syndromes; Lupus Erythematosus, Systemic; Leukemia, Myeloid, Acute | Details |
| Vibecotamab | XmAb-14045 | Phase 1 Clinical | Xencor | Hematologic Neoplasms; Leukemia, Myeloid; Blastic Plasmacytoid Dendritic Cell Neoplasm; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute | Details |
| IMGN-632 | IMGN-632 | Phase 2 Clinical | Immunogen | Myeloproliferative Disorders; Blastic Plasmacytoid Dendritic Cell Neoplasm; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute | Details |
| MB-102 (Mustang Bio) | MB-102 | Phase 2 Clinical | Mustang Bio, City Of Hope National Medical Center | Blastic Plasmacytoid Dendritic Cell Neoplasm; Leukemia, Myeloid, Acute | Details |
| UCART-123 | UCART-123 | Phase 1 Clinical | Cellectis | Blastic Plasmacytoid Dendritic Cell Neoplasm; Leukemia, Myeloid, Acute | Details |
This web search service is supported by Google Inc.
A-Z